维普期刊资源整合服务平台（V6.5）

139篇 您的检索式：作者名="Sehn"

选中清除导出查看参考文献查看引证文献引用追踪共7页首页上一页第1页下一页末页 /7 跳转

	题名	作者	年代	出处	被引量
1	: Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas 显示文摘	Hoglund M Sehn L Connors JM	2004	Genes Chromosomes Cancer2004，39，：	1
2	Introduction of combined CHOP plus rituximab therapy dramatically improved out- come of diffuse large B-cell lymphoma in british columbia 显示文摘	Sehn L H Donaldson J Chhanabhai M	2005	Clin Oneol2005，23，22：	1
3	Effects of temperature on biological degradation of phenols,benzoates and phthalates under methanogenic conditions显示文摘	Levén L Sehnürer A		0，，：	1
4	Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma:a phase Ⅱ study by the National Cancer Institute of Canada Clinical Trials Group显示文摘	Sehn LH MacDonald D Rubin S		0，，25：	1
5	The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP显示文摘	Sehn LH Berry B Chhanabhai M	2007	Blood2007，109，5：	1
6	Optimal use of prognostic factors in non - hodgkin lymphoma 显示文摘	Sehn LH	2006	Hematology Am Soc Hematol Educ Program2006，，：	1
7	An enhanced international prognostic index(NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era显示文摘	Zhou Z Sehn LH Rademaker AW	2014	Blood2014，123，6：	1
8	Optimal use of prognostic factors in non-Hodgkin lymphoma显示文摘	Sehn LH	2006	Hematology Am Soc Hematol Educ Program2006，7，1：	1
9	The revised International Prognostic Index ( R - IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lyrn- phoma treated with R-CHOP显示文摘	Sehn LH Berry B Chhanahhai M et a!	2007	Blood2007，109，5：	1
10	Diffuse large B--cell lymphoma: optimiz- hag outcome in the context of clinical and biologic heterogeneity 显示文摘	Sehn LH Gascoyne RE)	2015	Blood2015，125，1：	1
11	The revisedinternational prognostic index ( R-IPI) is a betterpredictor of outcome than the standard IPI for patientswith diffuse large B-cell lymphoma treated with R-CHOP显示文摘	Sehn LH Berry B Chhanabhai M	2007	Blood2007，109，5：	1
12	An enhanced Interna- tional Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era显示文摘	Zhou Z Sehn LH Rademaker AW	2014	Blood2014，123，6：	1
13	A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies显示文摘	Sehn LH Assouline SE Stewart DA	2012	Blood2012，119，22：	1
14	Postcontrast time-of-flight MR angiography demonstrating collateral flow in acute stroke显示文摘	Sohn CH Sehn SI Chang HW	2007	Stroke2007，38，4：	1
15	Randomized phase Ⅱ trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell Non-Hodgkin lymphoma: final analysis of the GAUSS study显示文摘	Sehn LH Goy A Offner FC	2015	J Clin Oncol2015，33，30：	1
16	Fluoride removal with extra low energy reverse osmosis membranes: Three years of large scale experience in Finland显示文摘	Sehn P	2008	Desalination2008，223，13：	1
17	An enhanced Interna- tional Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era显示文摘	Zhou Z Sehn LI-'I Rademaker AW	2014	Blood2014，123，6：	1
18	The revised Internation- al Prognostic Index (R- IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R- CHOP 显示文摘	Sehn LH Berry B Chhanabhai M	2007	Blood2007，109，5：	1
19	A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British columbia cancer agency 显示文摘	Ramadan KM Shenkier T Sehn LH	2007	Ann Oncol2007，18，1：	1
20	An enhanced Interna- tional Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era 显示文摘	Zhou Z Sehn LH Rademaker AW	2014	Blood2014，123，6：	1

返回顶部每页显示：

共7页首页上一页第1页下一页末页 /7 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示